MetaCap

Akari Therapeutics (AKTX) vs Lipocine (LPCN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Lipocine (LPCN) has outperformed Akari Therapeutics (AKTX) over the past year, losing 53.2% versus a loss of 60.1%. Over five years, LPCN leads with a -92.3% price change compared with -99.5% for AKTX. Akari Therapeutics is the larger company by market cap ($16.7 million vs $16.4 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AKTX-60.11%LPCN-53.16%
+273%+87%-100%
Nov 21, 20251 yearNov 20, 2026
AKTX-99.41%LPCN-92.56%
+66%-21%-108%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AKTX versus LPCN key metrics
MetricAKTXLPCN
Share price$7.18$1.48
Market cap$16.70M$16.39M
1-day change+7.00%-1.33%
YTD return-37.89%-81.57%
1-year return-60.11%-53.16%
5-year return-99.47%-92.30%
EPS (TTM)$0.00$-1.32
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$1.98M
Revenue growth (YoY)—-82.35%
Net income (latest FY)$-17.30M$-9.63M
Operating margin—-524.69%
Net margin—-487.06%
52-week high$29.32$12.37
52-week low$3.02$1.36
Distance from 52-week high-75.51%-88.04%
Analyst consensusnonenone
Avg. price target upside+255.15%+237.84%
Average volume58.54K1.84M
Shares outstanding2.33M11.07M
Employees514
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Akari Therapeutics

AKTX stock →

Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing.

Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees

About Lipocine

LPCN stock →

Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs using its proprietary delivery technology. The company offers TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.

Health Care · Biotechnology: Pharmaceutical Preparations · 14 employees

AKTX vs LPCN FAQ

Which is bigger, Akari Therapeutics or Lipocine?

Akari Therapeutics (AKTX) is larger, with a market capitalization of $16.70M compared with $16.39M for Lipocine (LPCN).

Which stock has performed better over the past year, AKTX or LPCN?

LPCN returned -53.16% over the past 12 months, compared with -60.11% for AKTX (price return, excluding dividends). Past performance does not predict future results.

Are Akari Therapeutics and Lipocine in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons